Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors;Utilidad de la FDG-PET en la evaluación precoz de la eficacia de imatinib (Glivec) en el tratamiento de tumores del estroma gastrointestinal

Revista Espanola de Medicina Nuclear

Volumn 26, Issue 2, 2007, Pages 100-102

  Garcia Gonzalez J ^a   Sanchez Salmon A ^a   Areses Manrique, C ^a   Leon Mateos L ^a   Barandela Salgado, J ^a   Lopez Lopez R ^a  

^a Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

Author keywords

c Kit protooncogene proteins; Fluorodeoxyglucose F18; Gastrointestinal stromal tumors; Imatinib mesysale; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RELAPSE; CASE REPORT; DISEASE COURSE; DRUG EFFICACY; DRUG UPTAKE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; METASTASIS; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 34247495536     PISSN: 02126982     EISSN: None     Source Type: Journal    
DOI: 10.1157/13099949     Document Type: Article

References (8)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical and molecular genetic features and differential diagnosis. Virchows Arch. 2001;4383:1-12.
2. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD. Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-80.
3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS. Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-16.
4. Blay JY, Bonvalot JS, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST consensus conference of 20-21 March 2004, under the auspicies of ESMO. Ann Oncol. 2005;16:566-78.
5. Choi H, Charnsangavej C, de Castro Faria S, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183:1619-26.
6. Van den Abbeele AD, Badawi RD. Use of positron emission tomography and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38 Suppl 5:S60-5.
7. Simo M, García JR, Soler M, Pérez G, López S, Lomena FJ. Role of FDG PET in the staging, recurrence and treatment response to imatinib (Glivec) in patients with gastrointestinal stromal tumors. Rev Esp Med Nucl. 2006;25:80-8.
8. Stroobants S, Goominne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-Positron emission tomography for early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer. 2003;39:2012-20.